HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells.

AbstractPURPOSE:
To evaluate the radiosensitization effect on solid tumors upon combination treatment with paclitaxel (TXL), including the effect on intratumor quiescent (Q) cells.
METHODS AND MATERIALS:
Mice bearing SCC VII or EL4 solid tumors received 5-bromo-2'-deoxyuridine (BrdU) continuously for 5 days to label all proliferating (P) cells. The mice then received gamma-irradiation with or without tirapazamine (TPZ) at various time points after TXL administration. Another group of mice received a series of test doses of gamma-rays while alive or after tumor clamping to obtain hypoxic fractions (HFs) in the tumors at various time points after TXL administration. Immediately after irradiation, the tumor cells were isolated and incubated with a cytokinesis blocker. The micronucleus (MN) frequency in cells without BrdU labeling (Q cells) was determined using immunofluorescence staining for BrdU. Meanwhile, 6 h after irradiation, the tumor cells were isolated from the solid tumors in another group of mice, and the apoptosis frequency in Q cells was also determined with immunofluorescence staining for BrdU. The MN and apoptosis frequency in total (P + Q) tumor cells were determined from the tumors that were not pretreated with BrdU. For the measurement of the HFs, the MN or apoptosis frequency of Q cells was then used to calculate the surviving fraction of Q cells from the regression line for the relationship between the MN or apoptosis frequency and the surviving fraction of total tumor cells.
RESULTS:
In both SCC VII and EL4 tumors, maximum values of mitotic index (MI) and apoptosis frequency were observed 9 and 24 h after TXL administration, respectively. However, on the whole, the apoptosis frequency for SCC VII was very low. gamma-Irradiation 9 h after TXL administration induced significant radiosensitization effects on the total cells of both tumors. Irradiation at 60 h had a more significant effect on total cells of EL4 tumor, but no significant effect on total cells of SCC VII tumor. Combined treatment with TXL induced no radiosensitization effect on Q cells in either tumor. The effect on Q cells was observed only after TPZ was administered. The HF of total cells in EL4 tumors decreased significantly 60 h after TXL administration.
CONCLUSION:
No radiosensitization effect upon combination treatment with TXL is induced in Q tumor cells. However, the effect on P cells is produced by irradiation at the time when the maximum values of MI are induced following TXL administration. In addition, for tumors that are susceptible to apoptosis after TXL administration alone, irradiation at the time of sufficient reoxygenation in tumors after TXL administration produces a greater radioenhancement effect on P cells.
AuthorsS I Masunaga, K Ono, M Suzuki, Y Nishimura, Y Kinashi, M Takagaki, H Hori, H Nagasawa, Y Uto, I Tsuchiya, S Sadahiro, C Murayama
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 50 Issue 4 Pg. 1063-72 (Jul 15 2001) ISSN: 0360-3016 [Print] United States
PMID11429234 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Radiation-Sensitizing Agents
  • Triazines
  • Tirapazamine
  • Bromodeoxyuridine
  • Paclitaxel
Topics
  • Animals
  • Apoptosis
  • Bromodeoxyuridine (metabolism)
  • Carcinoma, Squamous Cell (radiotherapy)
  • Cell Survival
  • Humans
  • Mice
  • Mice, Inbred C3H
  • Micronucleus Tests
  • Neoplasms (physiopathology, radiotherapy)
  • Paclitaxel (therapeutic use)
  • Radiation Tolerance
  • Radiation-Sensitizing Agents (therapeutic use)
  • Radiobiology
  • Radiotherapy Dosage
  • Time Factors
  • Tirapazamine
  • Triazines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: